In situ Breast Cancer Treatment

In situ Breast Cancer Treatment

In situ breast cancer treatment options are for stage 0 breast cancer. There are two types of in situ (Stage 0) breast cancer, lobular carcinoma in situ (LCIS) and ductual carcinoma in situ (DCIS), which are also referred to as non-invasive forms of breast cancer. Each of these forms of Stage 0 breast cancer are treated differently.

 

Ductual Carcinoma in Situ (DCIS)

This is a condition where abnormal cells are found in the lining of the breast duct. While it can become invasive cancer and spread to other parts of the body, it is not possible to predict when and if this will happen.

In situ breast cancer treatment options for ductual carcinoma in situ include may include one or more of the following:

Surgery for In situ Breast Cancer Treatment
Depending on how large of an area the ductual carcinoma in situ is located, one of two types of surgery may be performed.
Breast-sparing surgery
The first, referred to as breast-sparing surgery (a lumpectomy or partial mastectomy), removes only the cancerous area of the breast.
Mastectomy
The second, known as a mastectomy (or bilateral prophylactic mastectomy) involves removal of the entire breast (or both breasts).
Radiation Therapy In situ Breast Cancer Treatment
For this form of non-invasive breast cancer, radiation therapy typically is recommended following a lumpectomy or partial mastectomy.
Hormone Therapy In situ Breast Cancer Treatment
Following surgery and/or radiation therapy, hormone therapy with tamoxifen (Nolvadex) also may be given to help reduce the risk of developing invasive breast cancer from ductual carcinoma in situ that has been classified as hormone receptor-positive.

Lobular Carcinoma in Situ (LCIS)

While lobular carcinoma in situ, another condition where abnormal cells are found in the glands of the breast that make milk (lobules), rarely leads to invasive breast cancer, it can increase the overall risk of developing breast cancer. While there is no specific anti-cancer treatment regimen that is typically given to treat lobular carcinoma in situ, many women may opt to follow one or more of the following treatment plans to help reduce their risk of developing breast cancer:

Observation
Once lobular carcinoma in situ is diagnosed, it is important to undergo yearly mammograms and MRIs to continuously observe and screen for the development of invasive breast cancer.
Surgery for In situ Breast Cancer Treatment
Some women may choose to have a bilateral prophylactic mastectomy (removal of both breasts) to help reduce their risk of developing full-blown breast cancer.
Hormone Therapy In situ Breast Cancer Treatment
Studies have shown that hormone therapies such as tamoxifen (Nolvadex) or raloxifene (Evista) may help prevent breast cancer in women who are at high-risk.
Tamoxifen
Used for more than 30 years to treat breast cancer, tamoxifen is given as a pill and works by blocking the activity of estrogen.
Raloxifene
Raloxifene works in a similar manner to tamoxifen but has not been used or studied for as long as tamoxifen.
Both therapies have serious side effect profiles that should be evaluated prior to starting therapy.

Related Articles


 

The information provided on CancerTreatment.net is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her health professional. This information is solely for informational purposes and does not constitute the practice of medicine. We encourage all visitors to see a licensed physician or nutritionist if they have any concerns regarding health issues related to diet, personal image and any other topics discussed on this site. Neither the owners or employees of CancerTreatment.net nor the author(s) of site content take responsibility for any possible consequences from any treatment, procedure, exercise, dietary modification, action or application of medication which results from reading this site. Always speak with your primary health care provider before engaging in any form of self treatment. Please see our Legal Statement for further information.